retatrutide safety trial Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide Phase 3 TRIUMPH-4 Results:

Counterfeit Botox that sickened people across the country in April 2024 (FDA) An August 2025 expos in Elle about bad actors and loose regulation in the medical spa industry included the story of a Boston woman who falsely claimed to be a registered nurse and injected patients with counterfeit products from Brazil and China

Their superiority lies in their potent formula, which has been proven to be effective in clinical trials and user experiences

Qsymia fits patients who prefer oral dosing, have moderate weight to lose (20 to 40 pounds), can tolerate the topiramate side effect profile, and have a budget constraint or insurance that doesnt cover GLP-1s for obesity

PMC6271067 TB-4 tissue repair actin sequestration, cytoskeletal organization, and Ac-SDKP release: Goldstein AL et al

Today Answer a few quick questions